A Phase 3 Trial in Participants With Obesity Due to Bardet-Biedl Syndrome or Alström Syndrome: Efficacy and Safety of the Melanocortin 4 Receptor Agonist Setmelanotide

Introduction: This randomized Phase 3 trial evaluated the effect of setmelanotide, a melanocortin 4 receptor agonist, on weight loss, hunger reduction, and safety outcomes in individuals (aged ≥6 years) with obesity and a genetically confirmed diagnosis of Bardet-Biedl syndrome (BBS) or Alström synd...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Endocr Soc
Autores principales: Haws, Robert, Clément, Karine, Dollfus, Hélène, Han, Joan C, Haqq, Andrea Maria, Martos-Moreno, Gabriel Angel, Mittleman, Robert, Stewart, Murray, Webster, Matt, Yanovski, Jack, Yuan, Guojun, Argente, Jesús
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2021
Materias:
Adipose Tissue, Appetite, and Obesity
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089587/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.002
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares